Effect of Alpha Lipoic Acid on Obesity Related Comorbidities
NCT ID: NCT00994513
Last Updated: 2010-09-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
70 participants
INTERVENTIONAL
2009-07-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALA
alpha lipoic acid 1200 mg/day
Alpha Lipoic Acid
1200 mg/day
Placebo
placebo 1200 mg/day
Placebo
1200 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alpha Lipoic Acid
1200 mg/day
Placebo
1200 mg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI≥25kg/m2
* Having at least one of the following risk factors: borderline hypertension (130mmHg≤SBP\<140mmHg or 85mmHg≤DBP\<90mmHg), dyslipidemia (fasting total cholesterol ≥240mg/dl or HDL-C\<40mg/dl), or impaired fasting glucose (fasting glucose levels between 6.1 and 7.0mmol/L)
* 18-60 years old
* Not on any antioxidant vitamin supplement
Exclusion Criteria
* History of hypertension, diabetes, coronary heart disease(CHD), cancer or liver disease
* Anything that would impede the subject from complying with the ALA treatment
* History of psychiatric problems
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xinjiang Medical University
OTHER
Augusta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical College of Georgia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xinjiang Medical University
Ürümqi, Xinjiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HAC08-07-02
Identifier Type: -
Identifier Source: org_study_id